......................... 62 Heat Biologics, Inc. Investigational Product: Viagenpumatucel -L Protocol HS110 -201 CONFIDENTIAL Version 4.0; 29 -Oct-2014 Page 16 of 84 9.7.10 Immune -related Time to Progression (irTTP) ................................ ................................ .....62 9.7.11 Time to Progression (TTP) ................................ ................................ ................................ ..62 9.7.12 6-month overall survival (6mOS) ................................ ................................ ........................ 62 9.7.13 12-month overall survival (12mOS) ................................ ................................